middle.news
How Is Emyria Leading Australia’s Psychedelic Therapy Revolution with Medibank Support?
2:13am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Is Emyria Leading Australia’s Psychedelic Therapy Revolution with Medibank Support?
2:13am on Saturday 30th of August, 2025 AEST
Key Points
Net loss narrowed to $3.14 million from $11.46 million in prior year
Revenue declined 37% to $1.39 million, primarily from clinical services
Acquisition of Mind Body Consulting (Pax Centre) enhances clinical offerings
Medibank funds MDMA-assisted therapy, first insurer-backed psychedelic treatment in Australia
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Emyria (ASX:EMD)
OPEN ARTICLE